AU3967297A - Use of gaba and nmda receptor ligands for the treatment of migraine headache - Google Patents

Use of gaba and nmda receptor ligands for the treatment of migraine headache

Info

Publication number
AU3967297A
AU3967297A AU39672/97A AU3967297A AU3967297A AU 3967297 A AU3967297 A AU 3967297A AU 39672/97 A AU39672/97 A AU 39672/97A AU 3967297 A AU3967297 A AU 3967297A AU 3967297 A AU3967297 A AU 3967297A
Authority
AU
Australia
Prior art keywords
gaba
treatment
nmda receptor
receptor ligands
migraine headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39672/97A
Inventor
Nancy C. Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cocensys Inc
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of AU3967297A publication Critical patent/AU3967297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU39672/97A 1996-08-01 1997-07-31 Use of gaba and nmda receptor ligands for the treatment of migraine headache Abandoned AU3967297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2293796P 1996-08-01 1996-08-01
US60022937 1996-08-01
PCT/US1997/013430 WO1998005337A1 (en) 1996-08-01 1997-07-31 Use of gaba and nmda receptor ligands for the treatment of migraine headache

Publications (1)

Publication Number Publication Date
AU3967297A true AU3967297A (en) 1998-02-25

Family

ID=21812205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39672/97A Abandoned AU3967297A (en) 1996-08-01 1997-07-31 Use of gaba and nmda receptor ligands for the treatment of migraine headache

Country Status (2)

Country Link
AU (1) AU3967297A (en)
WO (1) WO1998005337A1 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
JP2008504329A (en) * 2004-06-29 2008-02-14 ヤド テクノロジーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of steroid-derived pharmaceutical compositions to treat disorders related to pathological processes within lipid rafts
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2097437T3 (en) * 2006-11-21 2015-06-29 Umecrine Cognition Ab THE USE OF PREGNANCY AND ANDROSTANOSTEROIDS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISEASES
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
JOP20180077A1 (en) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
GB2460350B (en) * 2008-04-25 2011-04-06 Kythera Biopharmaceuticals Inc Intermediates for the preparation of bile acids
CN101585862B (en) * 2008-05-20 2014-12-17 梅克芳股份公司 Steroids
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5934645B2 (en) 2009-09-11 2016-06-15 プロビオドルグ エージー Heterocyclic derivatives as glutaminyl cyclase inhibitors
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (en) 2010-03-10 2015-03-25 プロビオドルグ エージー Heterocyclic inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
AU2010359050B2 (en) 2010-08-12 2016-03-17 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
FR2973031B1 (en) * 2011-03-23 2013-11-29 Univ Strasbourg DERIVATIVES OF ALLOPREGNANOLONE AND EPIALLOPREGNANOLONE AND USES THEREOF FOR TREATING A NEUROPATHOLOGICAL CONDITION
JP2014521662A (en) * 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Novel 17β-heteroaryl substituted steroids as modulators of GABAA receptors
HRP20230747T1 (en) * 2011-09-08 2024-01-05 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN119192266A (en) * 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-disubstituted 19-norpregnane compounds, compositions, and uses thereof
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (en) 2012-08-21 2015-07-21 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus.
MX365644B (en) * 2012-12-18 2019-06-10 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same.
SMT201800657T1 (en) 2013-03-13 2019-01-11 Sage Therapeutics Inc Neuroactive steroids and methods of use thereof
WO2014151411A1 (en) * 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
JP6470258B2 (en) * 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド 19-nor C 3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
ES2807264T3 (en) * 2013-04-17 2021-02-22 Sage Therapeutics Inc 19-nor neuroactive steroids for treatment methods
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (en) 2013-08-23 2021-08-12 Sage Therapeutics Inc Neuroactive steroids, compositions and uses thereof
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
HRP20201126T1 (en) * 2014-05-29 2020-12-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CZ2014575A3 (en) * 2014-08-26 2016-02-24 Ústav organické chemie a biochemie AV ČR, v.v.i. Amphiphilic compounds exhibiting neuroprotecting activity
JOP20200195A1 (en) 2014-09-08 2017-06-16 Sage Therapeutics Inc Neuroactive steroids and formulations, and their uses
ME03809B (en) 2014-10-16 2021-04-20 Sage Therapeutics Inc COMPOSITIONS AND METHODS OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
US10577390B2 (en) * 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) * 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) * 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MX382122B (en) 2015-07-06 2025-03-13 Sage Therapeutics Inc OXYSTEROLS AND METHODS OF USING THEM.
PL3319611T3 (en) 2015-07-06 2021-07-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HK1258616A1 (en) 2016-03-08 2019-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US20190233465A1 (en) * 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (en) * 2016-07-11 2019-05-15 Sage Therapeutics Inc NEUROACTIVE STEROIDS SUBSTITUTED FOR C17, C20 AND C21 AND THEIR USE PROCEDURES
PT3519422T (en) 2016-09-30 2022-12-05 Sage Therapeutics Inc C7 substituted oxysterols and methods as nmda modulators
DK4105223T3 (en) 2016-10-18 2025-07-07 Sage Therapeutics Inc OXYSTEROLS AND METHODS OF USING THEREOF
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
EP3728284B1 (en) * 2017-12-22 2024-08-21 Sage Therapeutics, Inc. 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
CN111741965B (en) * 2017-12-22 2024-06-25 萨奇治疗股份有限公司 Compositions and methods for treating central nervous system diseases
MA51568A (en) 2018-01-12 2021-04-21 Sage Therapeutics Inc AZA-, OXA AND THIA-PREGNAN-20-ONE-3.ALPHA.-OL COMPOUNDS FOR USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
EP3750909B1 (en) * 2018-02-11 2025-03-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN114656514B (en) * 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 Steroid derivative regulator and preparation method and application thereof
US20210300962A1 (en) * 2018-08-02 2021-09-30 Puretech Lyt, Inc. Lipid prodrugs of pregnane neurosteroids and uses thereof
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN111040015B (en) * 2018-10-15 2022-03-18 南京诺瑞特医药科技有限公司 19-nor-C21 substituted steroid derivatives
CA3116892A1 (en) * 2018-10-19 2020-04-23 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
CN109503694A (en) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 A kind of novel GABAAReceptor modulators and application thereof
IL283629B2 (en) * 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and their methods of use
GB201820887D0 (en) * 2018-12-20 2019-02-06 Nzp Uk Ltd Compounds
CN116589521B (en) * 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 Steroidal compounds, uses and preparation methods thereof
CN121652218A (en) * 2019-01-08 2026-03-13 成都康弘药业集团股份有限公司 Steroidal compounds, their uses and preparation methods
EP3911331A4 (en) * 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
JP7648538B2 (en) * 2019-04-27 2025-03-18 ヘルス リサーチ インコーポレイテッド Coumarin-modified androgens for the treatment of prostate cancer
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth
CR20240234A (en) * 2019-05-31 2024-07-09 Sage Therapeutics Inc NEUROACTIVE STEROIDS AND THEIR COMPOSITIONS (Divisional 2021-629)
JP7787635B2 (en) 2019-06-27 2025-12-17 セージ セラピューティクス， エルエルシー Compositions and methods for treating CNS disorders
US20230257415A1 (en) * 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
EP4041226A1 (en) * 2019-10-02 2022-08-17 Praxis Precision Medicines, Inc. Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
TW202143976A (en) * 2020-03-18 2021-12-01 美商賽吉醫療公司 Neuroactive steroids and their methods of use
WO2023023650A1 (en) * 2021-08-20 2023-02-23 University Of Mississippi Allopregnanolone analogues for hiv viremia and neurotoxicity protection
CN115974950A (en) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 A kind of 3-alkylated steroid intermediate and its preparation and application
WO2025119319A1 (en) * 2023-12-08 2025-06-12 山东绿叶制药有限公司 Crystal form of gabaa receptor modulator, preparation method therefor and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches

Also Published As

Publication number Publication date
WO1998005337A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
AU3967297A (en) Use of gaba and nmda receptor ligands for the treatment of migraine headache
AU7264298A (en) Apparatus and method for the reduction of snoring
AU697510B1 (en) Method and apparatus for the dry grinding of solids
AU4838097A (en) Apparatus for the treatment of specimens
EP0868543A4 (en) Improved polishing slurries and methods for their use
AU3793697A (en) Apparatus and methods for the disinfection of fluids
AU2223895A (en) Massaging apparatus
AU1125797A (en) Apparatus and methods for ultrasonically enhanced fluid delivery
AU5608196A (en) Method of and apparatus for controlled dispensing of two-part bonding, casting and similar fluids and the like
AU2607295A (en) Drum coating: apparatus and methods
AU6124996A (en) Certain arylsulfonamido-substituted hydroxamic acids for the treatment of certain tumors
AU3323195A (en) Method and apparatus for direct retinal projection
AU2675095A (en) Indol derivatives useful for the treatment of migraine, composition and utilization
EP0732351A3 (en) Process and apparatus for the preparation of polyamides
HUP9802307A3 (en) Process for the hydrogenation of imines and for the preparation of chloro-acetanilide derivatives
AU2821295A (en) Compositions and methods for the treatment of tumors
AU4902596A (en) Multi-function fluid treatment system and method for using the same
AU2173597A (en) Process for the preparation of tenidap
HUP9903852A3 (en) Process for the preparation of contrast agents
AU6733496A (en) Iridium-diphosphine complexes and process for the hydrogenation of imines
AU4818897A (en) Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens and tumors
AU4272996A (en) Means for treatment of particle mass
AU1489999A (en) Apparatus and procedure for the coating of objects
AU2627395A (en) Methods for and machines for use in the lining of pipelines and passageways
AU5892296A (en) Device for polishing the interiors of pipes and fittings